Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Listen to this article in summarized format Also Read | Dr Reddy's gets nod to roll out generic oral semaglutide drug The sharp decline is fuelled by a rapid expansion in manufacturing, widening supplier base, and expiry of patents in key markets, including India
The three most recent Phase 3 readouts are: TRIUMPH-4 (December 2025) showing 28.7% weight reduction at 68 weeks in obesity with knee osteoarthritis, TRANSCEND-T2D-1 (March 2026) showing A1C reductions up to 2.0% and 16.8% weight loss at 40 weeks in type 2 diabetes, and TRIUMPH-1 (May 2026) showing up to 25.0% weight reduction at 80 weeks in the pivotal obesity trial
These small, consistent habits power everyday wellbeing
Medication is advertised at $99 per month
US$ 26.50
US$ 21.79
US$ 26.40
US$ 23.44
